335 Results

People

  1. Pastores
    Pastores
  2. Brennan
    Brennan
  3. Sepkowitz
    Sepkowitz
  4. Horwitz
    Horwitz
  5. Dunkel
    Dunkel
  6. Heller
    Heller
  7. Herr
    Herr
  8. Kelsen
    Kelsen
  9. Zelenetz
    Zelenetz
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (168)
  2. Hematologic Malignancies, Division of (78)
  3. Center for Hematologic Malignancies (74)
  4. Solid Tumor Oncology Division (74)
  5. Surgery (69)
  6. Survivorship Research (47)
  7. Anesthesiology and Critical Care Medicine (30)
  8. Adult Leukemia (28)
  9. Center for Pancreatic Cancer Research (28)
  10. Division of Subspecialty Medicine (27)
  1. "sepsis"
Formats
  1. Journal Article (305)
  2. Review (13)
  3. Editorial (5)
  4. Research Letter (4)
  5. Conference Paper (3)
  6. Correspondence (3)
  7. Guidelines (2)
Groups
  1. Department of Medicine (168)
  2. Hematologic Malignancies, Division of (78)
  3. Center for Hematologic Malignancies (74)
  4. Solid Tumor Oncology Division (74)
  5. Surgery (69)
  6. Survivorship Research (47)

More Groups

People
  1. Stephen Pastores (22)
  2. Murray Brennan (11)
  3. Kent Sepkowitz (9)
  4. Martin Tallman (9)
  5. Steven Horwitz (8)
  6. Andrew Zelenetz (7)

More People

Years
  1. 2025 (19)
  2. 2024 (26)
  3. 2023 (19)
  4. 2022 (12)
  5. 2021 (7)
  6. 2020 (24)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Cancer (15)
  3. Lancet Oncology (13)
  4. Leukemia and Lymphoma (12)
  5. Blood (11)
  6. Journal of Urology (8)

More Publications

Publishers
  1. Elsevier Science, Inc. (36)
  2. Elsevier Inc. (33)
  3. American Society of Clinical Oncology (24)
  4. Wiley Blackwell (22)
  5. Lippincott Williams & Wilkins (19)
  6. Nature Publishing Group (18)

More Publishers

Results (335)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inter-α-inhibitor heavy chain H4 and sepsis-related coagulation disturbances: Another link between innate immunity and coagulation
    Journal Article

    Larsen, J. B.; Pihl, R.; Aggerbeck, M. A.; Larsen, K. M.; Hvas, C. L.; Johnsen, N.; Christensen, M. G.; Praetorius, H.; Hvas, A. M.; Thiel, S.
    Research and Practice in Thrombosis and Haemostasis (2023)

    Fulltext@MSK | Save
  • Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: A randomized clinical trial
    Journal Article

    D'Angelica, M. I.; Ellis, R. J.; Liu, J. B.; Brajcich, B. C.; Gönen, M.; Thompson, V. M.; Cohen, M. E.; Seo, S. K.; Zabor, E. C.; Babicky, M. L.; more...
    JAMA - Journal of the American Medical Association (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
    Journal Article

    Harding, J. J.; Piha-Paul, S. A.; Shah, R. H.; Murphy, J. J.; Cleary, J. M.; Shapiro, G. I.; Quinn, D. I.; Braña, I.; Moreno, V.; Borad, M.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Acquisition and analysis of microcirculation image in septic model rats
    Journal Article

    Ye, C.; Kawasaki, M.; Nakano, K.; Ohnishi, T.; Watanabe, E.; Oda, S.; Nakada, T. A.; Haneishi, H.
    Sensors (2022)

    Fulltext@MSK | Save
  • A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia
    Journal Article

    Prebet, T.; Goldberg, A. D.; Jurcic, J. G.; Khaled, S.; Dail, M.; Feng, Y.; Green, C.; Li, C.; Ma, C.; Medeiros, B. C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: Primary results of the randomized phase III IMpassion050 trial
    Journal Article

    Huober, J.; Barrios, C. H.; Niikura, N.; Jarząb, M.; Chang, Y. C.; Huggins-Puhalla, S. L.; Pedrini, J.; Zhukova, L.; Graupner, V.; Eiger, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
    Correspondence

    Fitzgerald, K. N.; Quesada, A. E.; von Keudell, G.; Raj, S.; Lewis, N. E.; Dogan, A.; Salles, G.; Palomba, M. L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial
    Journal Article

    Shanafelt, T. D.; Wang, X. V.; Hanson, C. A.; Paietta, E. M.; O'Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The ABVD’s of cooperative trials in pediatric Hodgkin lymphoma: The India experience
    Editorial

    Rodriguez-Hernandez, A.; Giulino-Roth, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save